Immunic (NASDAQ:IMUX) Upgraded to Strong-Buy by Leerink Partnrs

Leerink Partnrs upgraded shares of Immunic (NASDAQ:IMUX) to a strong-buy rating in a research note released on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for Immunic’s Q3 2024 earnings at ($0.22) EPS, Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.99) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.41) EPS.

IMUX has been the topic of a number of other research reports. B. Riley began coverage on Immunic in a report on Tuesday, August 27th. They set a buy rating and a $6.00 target price on the stock. Piper Sandler reiterated an overweight rating and set a $28.00 price objective on shares of Immunic in a research report on Tuesday, July 16th. StockNews.com upgraded Immunic from a sell rating to a hold rating in a research report on Tuesday, August 13th. Finally, Leerink Partners reissued an outperform rating and set a $5.00 price objective on shares of Immunic in a research note on Monday. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Immunic currently has an average rating of Buy and a consensus price target of $11.20.

Immunic Trading Down 2.0 %

Shares of IMUX stock opened at $1.49 on Monday. The firm has a fifty day simple moving average of $1.39 and a 200-day simple moving average of $1.31. The company has a market capitalization of $134.22 million, a PE ratio of -0.81 and a beta of 1.82. Immunic has a twelve month low of $0.95 and a twelve month high of $1.92.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. During the same quarter last year, the company posted ($0.54) EPS. Equities research analysts predict that Immunic will post -0.94 EPS for the current year.

Institutional Trading of Immunic

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in shares of Immunic during the 1st quarter worth about $25,000. Sierra Summit Advisors LLC bought a new position in Immunic during the fourth quarter valued at approximately $487,000. Ikarian Capital LLC lifted its stake in Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after acquiring an additional 1,162,378 shares during the last quarter. Vanguard Group Inc. grew its position in Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of Immunic during the 1st quarter worth $9,266,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.